Fetal Risks from Lurbinectedin Exposure
Lurbinectedin (Zepzelca), an alkylating agent for small cell lung cancer, carries significant fetal risks. It is classified as Pregnancy Category D by the FDA, indicating positive evidence of human fetal risk based on adverse reaction data, though potential benefits may warrant use in life-threatening situations.[1] Animal studies show embryofetal toxicity, including post-implantation loss, decreased fetal weights, and fetal malformations like head and limb defects at doses below human equivalents.[2]
Evidence from Studies and Labeling
Nonclinical reproductive toxicology in rats and rabbits revealed dose-dependent embryo-fetal lethality and structural abnormalities. No adequate human pregnancy data exist due to the drug's rarity in pregnant patients, but its genotoxic mechanism—binding DNA and inhibiting cell proliferation—suggests high teratogenic potential.[3] The Zepzelca label advises avoiding pregnancy and using effective contraception during treatment and for 6 months after the last dose for women of reproductive potential.[1]
Recommendations for Pregnant Patients or Exposure
Discontinue lurbinectedin if pregnancy occurs. Verify pregnancy status before starting therapy. For accidental exposure, consult teratogen information services; no specific reversal exists, but fetal monitoring via ultrasound is standard. Sperm banking is advised for male patients due to fertility risks.[1][2] Breastfeeding is not recommended during treatment and for 2 weeks after, as the drug may pass into milk.[3]
Comparison to Similar Cancer Drugs
Like other alkylators (e.g., cyclophosphamide), lurbinectedin poses miscarriage, birth defects, and growth restriction risks. Unlike some targeted therapies (e.g., trastuzumab), it lacks a safer pregnancy profile. Providers weigh maternal survival against fetal harm, often opting for termination counseling in early pregnancy.[4]
Regulatory Warnings and Reporting
FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for Zepzelca, mandating contraception education. Report exposures to the FDA MedWatch program or manufacturer Jazz Pharmaceuticals for post-marketing surveillance.[1]
[1]: Zepzelca Prescribing Information (FDA)
[2]: Drugs.com - Lurbinectedin Pregnancy
[3]: RxList - Zepzelca
[4]: MotherToBaby - Alkylating Agents